SOUTH SAN FRANCISCO, Calif., June 15 /PRNewswire/ -- Athenagen, Inc., a privately held biopharmaceutical company, reported today that its lead compound, GTS-21, a novel, orally active alpha-7 nicotinic acetylcholine (nACh) receptor agonist, demonstrated cognition enhancement activity in a proof-of-concept study in patients with schizophrenia. The study was published in the June issue of the Archives of General Psychiatry (2006; 63:630-638), a peer-reviewed publication of the American Medical Association.
